drugset / Trial / NCT03555916

Botulinum Toxin Injections for Oral Neuropathic Pain

NCT03555916 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

Peripheral painful traumatic trigeminal neuropathy (PPTTN) are poorly relieved by existing treatments which in addition induce many adverse effects. BTX, which blocks the exocytosis of neurotransmitters, can be captured by axonal retrograde transport in primary nociceptive neurons. Injected in the painful area, it might therefore inhibit the release of algogenic neurotransmitters, at both the peripheral and central levels and thus reduce pain. One study reported such an effect in neuropathic spinal pain. A recent study reported an analgesic effect in trigeminal neuralgia.

Timeline

Start
2019-04-04
Primary completion
2022-07-19
Completion
2022-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 50 iu Other

Indications